Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer's Disease: Are Immunotherapies Effective or Off-Target?. (June 2022)

• Record Type: Journal Article
• Authors: Shi, Mingchao; Chu, Fengna; Tian, Xiaoping; Aerqin, Qiaolifan; Zhu, Feiqi; Zhu, Jie
• Is Part Of: Neuroscientist. Volume 28:Number 3(2022)
• Page Start: 254
• Page End: 270
• Publication Date: 2022-06
• Subjects: Alzheimer's disease -- adaptive immune system -- aging -- immunotherapies -- inflammation; Neurosciences -- Periodicals; Neurology -- Periodicals; Neurobiology -- Periodicals; 616.8005
• DOI: 10.1177/1073858420987224
• Languages: English
• ISSNs: 1073-8584

Abstract

The pathogenesis of Alzheimer's disease (AD) is complex. Still it remains unclear, which resulted in all efforts for AD treatments with targeting the pathogenic factors unsuccessful over past decades. It has been evidenced that the innate immune is strongly implicated in the pathogenesis of AD. However, the role of adaptive immune in AD remains mostly unknown and the results obtained were controversial. In the review, we summarized recent studies and showed that the molecular and cellular alterations in AD patients and its animal models involving T cells and B cells as well as immune mediators of adaptive immune occur not only in the peripheral blood but also in the brain and the cerebrospinal fluid. The risk factors that cause AD contribute to AD progress by affecting the adaptive immune, indicating that adaptive immunity proposes a pivotal role in this disease. It may provide a possible basis for applying immunotherapy in AD and further investigates whether the immunotherapies are effective or off-target?